Transplantation of Multipotent Progenitor Cells in Stroke

Verfaillie博士及其同事开发的多能祖细胞（MPC） 在明尼苏达大学，似乎有使他们非常适合的属性， 干细胞疗法Athersys，Inc.拥有这些细胞的所有权我们最近 与Athersys，Inc.建立合作关系它发展了制造业， 技术，使这些细胞可用于临床使用。Athersys，Inc.将为我们提供这些细胞。 我们在啮齿动物中的初步数据表明，这些细胞作为中风的治疗方法是非常有前途的。在 为了开发这些细胞在中风中的效用，我们提出了一种翻译方案。拟议 一组实验将作为进行MPCs移植的临床前基础， 缺血性中风患者。脑卒中后MFC的可行性、安全性和最佳剂量及移植时机 在成年缺血性中风的啮齿动物模型中产生功效。的 以下具体目标将作为里程碑，并有“进行和不进行”的标准。 具体目标1：确定“长期”（即，移植后6个月）IV大鼠的疗效 短暂性大脑中动脉闭塞模型中的MPC。 具体目标2：评价Athersys，Inc.生产的IV人MPC的长期疗效。 根据GMP生产方案， 动脉闭塞模型 具体目标3：评估IV人MPC实现长期行为 暴露于短暂性大脑中动脉的雄性和雌性以及成年和老年大鼠中的获益 动脉闭塞模型 具体目标4：证明IV人MPC实现长期行为 永久性大脑中动脉结扎模型的益处。 具体目标5：表征同种异体大鼠MPC中的干细胞组织相容性， 异种人MPCs，以进一步提供IV MPCs在大鼠缺血性卒中模型中的安全性。 具体目标6：召开IND FDA准备会议，并收集文件进行归档 缺血性卒中干细胞治疗IND。 该提案扩展了我们确定干细胞治疗中风益处的科学平台。

Multipotent progenitor cells (MPCs), developed by Dr. Verfaillie and co-workers at the University of Minnesota, appear to have the properties which make them highly suitable as a stem cell therapy. Athersys, Inc. has the proprietary rights to these cells. We have recently developed a collaborative relationship with Athersys, Inc. which has developed manufacturing techniques to make these cells available for clinical use. Athersys, Inc. will supply these cells to us. Our preliminary data in rodents indicate that these cells are quite promising as a therapy for stroke. In order to develop the utility of these cells in stroke, we propose a translational protocol. The proposed set of experiments will serve as the preclinical basis for proceeding with transplantation of MPCs in ischemic stroke patients. Feasibility, safety, and optimal MFC dose and transplantation timing poststroke for producing efficacy in rodent models of adult ischemic stroke will be examined. The following specific aims will serve as milestones, with "go and no-go" criteria. ¿ Specific Aim 1: Determine the "long-term" (i.e., 6 months post-transplantation) efficacy of IV rat MPCs in transient middle cerebral artery occlusion model. ¿ Specific Aim 2: Evaluate the long-term efficacy of IV human MPCs produced by Athersys, Inc. according to GMP manufacturing protocols in a GLP xenogeneic transient middle cerebral artery occlusion model. ¿ Specific Aim 3: Assess the efficacy of IV human MPCs to achieve long-term behavioral benefits in male and female, and adult and aged rats exposed to transient middle cerebral artery occlusion model. ¿ Specific Aim 4: Demonstrate the efficacy of IV human MPCs to achieve long-term behavioral benefits in permanent middle cerebral artery ligation model. ¿ Specific Aim 5: Characterize stem cell histocompatibility in allogeneic rat MPCs and xenogeneic human MPCs to further provide safety of IV MPCs in rat ischemic stroke model. ¿ Specific Aim 6: Conduct IND FDA preparation meetings and assemble documents for filing IND for stem cell therapy in ischemic stroke. This proposal extends our scientific platform for determining the benefit of stem cell therapy in stroke.